Literature DB >> 31891715

Exoskeletal-Assisted Walking During Acute Inpatient Rehabilitation Leads to Motor and Functional Improvement in Persons With Spinal Cord Injury: A Pilot Study.

Chung-Ying Tsai1, Andrew D Delgado2, William J Weinrauch2, Nicholas Manente2, Isaiah Levy2, Miguel X Escalon2, Thomas N Bryce2, Ann M Spungen3.   

Abstract

OBJECTIVE: To explore the potential effects of incorporating exoskeletal-assisted walking (EAW) into spinal cord injury (SCI) acute inpatient rehabilitation (AIR) on facilitating functional and motor recovery when compared with standard of care AIR.
DESIGN: A quasi-experimental design with a prospective intervention group (AIR with EAW) and a retrospective control group (AIR only).
SETTING: SCI AIR facility. PARTICIPANTS: Ten acute inpatient participants with SCI who were eligible for locomotor training were recruited in the intervention group. Twenty inpatients with SCI were identified as matched controls by reviewing an AIR database, Uniform Data System for Medical Rehabilitation, by an individual blinded to the study. Both groups (N=30) were matched based on etiology, paraplegia/tetraplegia, completeness of injury, age, and sex. INTERVENTION: EAW incorporated into SCI AIR. MAIN OUTCOME MEASURES: FIM score, International Standards for Neurological Classification of Spinal Cord Injury Upper Extremity Motor Score and Lower Extremity Motor Scores (LEMS), and EAW session results, including adverse events, walking time, and steps.
RESULTS: Changes from admission to discharge LEMS and FIM scores were significantly greater in the intervention group (LEMS change: 14.3±10.1; FIM change: 37.8±10.8) compared with the control group (LEMS change: 4.6±6.1; FIM change: 26.5±14.3; Mann-Whitney U tests: LEMS, P<.01 and FIM, P<.05). One adverse event (minor skin abrasion) occurred during 42 walking sessions. Participants on average achieved 31.5 minutes of up time and 18.2 minutes of walk time with 456 steps in one EAW session.
CONCLUSIONS: Incorporation of EAW into standard of care AIR is possible. AIR with incorporated EAW has the potential to facilitate functional and motor recovery compared with AIR without EAW.
Copyright © 2019 American Congress of Rehabilitation Medicine. All rights reserved.

Entities:  

Keywords:  Inpatients; Rehabilitation; Spinal cord injuries; Walking

Mesh:

Year:  2019        PMID: 31891715     DOI: 10.1016/j.apmr.2019.11.010

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  5 in total

Review 1.  Wearable powered exoskeletons for gait training in tetraplegia: a systematic review on feasibility, safety and potential health benefits.

Authors:  Gonzalo Rodriguez Tapia; Ioannis Doumas; Thierry Lejeune; Jean-Gabriel Previnaire
Journal:  Acta Neurol Belg       Date:  2022-07-17       Impact factor: 2.471

Review 2.  Overground robotic training effects on walking and secondary health conditions in individuals with spinal cord injury: systematic review.

Authors:  Federica Tamburella; Matteo Lorusso; Marco Tramontano; Silvia Fadlun; Marcella Masciullo; Giorgio Scivoletto
Journal:  J Neuroeng Rehabil       Date:  2022-03-15       Impact factor: 4.262

3.  Knowledge Gaps in Biophysical Changes After Powered Robotic Exoskeleton Walking by Individuals With Spinal Cord Injury-A Scoping Review.

Authors:  Christopher C H Yip; Chor-Yin Lam; Kenneth M C Cheung; Yat Wa Wong; Paul A Koljonen
Journal:  Front Neurol       Date:  2022-03-10       Impact factor: 4.003

4.  Comparison of Efficacy of Lokomat and Wearable Exoskeleton-Assisted Gait Training in People With Spinal Cord Injury: A Systematic Review and Network Meta-Analysis.

Authors:  Lingjie Zhang; Fabin Lin; Lei Sun; Chunmei Chen
Journal:  Front Neurol       Date:  2022-04-13       Impact factor: 4.086

5.  Total flavonoids of hawthorn leaves promote motor function recovery via inhibition of apoptosis after spinal cord injury.

Authors:  Qiong Zhang; Yin Xiong; Bo Li; Gui-Ying Deng; Wen-Wen Fu; Bai-Chuan Cao; Shao-Hui Zong; Gao-Feng Zeng
Journal:  Neural Regen Res       Date:  2021-02       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.